GlaxoSmithKline’s triple drug inhaler for the treatment of chronic obstructive pulmonary disease (COPD) will be released in Korea, the company said Monday.
The Ministry of Food and Drug Safety approved local sales of Trelegy Ellipta (ingredient: fluticasone furoate, vilanterol, umeclidinium) on Friday.
|GSK’s Trelegy Ellipta (Credit: GSK)|
Trelegy Ellipta is the first triple treatment that combined inhaler-type corticosteroid fluticasone furoate with a long-acting muscarinic antagonist (LAMA) umeclidinium and a long-acting beta 2-adrenoceptor agonist (LABA) vilanterol.
The treatment obtained the indication for moderate to severe COPD in adult patients whose symptoms did not improve with the combo treatment of fluticasone furoate and vilanterol. COPD patients can inhale the drug only once a day.
In other words, COPD patients whose symptoms were not adequately controlled with Relvar Ellipta (ingredient: fluticasone furoate, vilanterol) or who were using umeclidinium additionally can be treated with Trelegy Ellipta.
Trelegy Ellipta won the license in the U.S. and Europe in 2017. Last month, the remedy added an indication for COPD patients with airflow limitation symptoms or acute exacerbation in the U.S.
According to FULFIL trial that compared the triple therapy with dual inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy and the IMPACT study on 10,355 patients, the triple treatment group showed a statistically significant decrease in moderate and severe aggravation rates.
The IMPACT trial that compared Trelegy Ellipta with Relvar Ellipta and Breo Ellipta, all supplied by GSK, the triple therapy group had a 15 percent reduction in annual deterioration rate and seizure rate.
<© Korea Biomedical Review, All rights reserved.>